Results 191 to 200 of about 28,560,894 (288)

Novel homozygous nonsense mutation in glucagon-like peptide-2 receptor gene resulting in severe human illness. [PDF]

JPGN Rep
Jaramishian C, Kamal S, Martín MG, Minkoff NZ.   +3 more
europepmc   +1 more source

A unique hormonal recognition feature of the human glucagon-like peptide-2 receptor. [PDF]

Cell Res, 2020
Sun W, Chen LN, Zhou Q, Zhao LH, Yang D, Zhang H, Cong Z, Shen DD, Zhao F, Zhou F, Cai X, Chen Y, Zhou Y, Gadgaard S, van der Velden WJC, Zhao S, Jiang Y, Rosenkilde MM, Xu HE, Zhang Y, Wang MW.   +20 more
europepmc   +1 more source

Incidental Resolution of Dopamine Agonist Induced Impulse Control Disorder with GLP‐1 Receptor Agonist

Movement Disorders Clinical Practice, EarlyView.
Hannah Kelly, Thomas Davis
wiley   +1 more source

Incretin‐Based Therapies: A Testable Hypothesis Linking Incretin Signaling, Mitochondrial Redox, and OXPHOS Efficiency

Obesity, EarlyView.
ABSTRACT Objective Incretin‐based obesity therapies (IBTs), especially GLP‐1 receptor agonists (GLP‐1 RAs), effectively treat obesity and improve comorbidities. However, their impact on energy metabolism is unclear. A recent case of acute generalized muscle weakness in a patient with mitochondrial myopathy after tirzepatide exposure raises concerns ...
Bryn Falahee, Caroline M. Apovian, Nawfal Istfan   +2 more
wiley   +1 more source

Glucagon-like peptide-2 pharmacotherapy activates hepatic Farnesoid X receptor-signaling to attenuate resection-associated bile acid loss in mice. [PDF]

Mol Metab
Reiner J, Mohebali N, Kurth J, Witte M, Prehn C, Lindner T, Berlin P, Elleisy N, Förster RH, Cecil A, Jaster R, Adamski J, Schwarzenböck SM, Vollmar B, Krause BJ, Lamprecht G.   +15 more
europepmc   +1 more source

Weight Self‐Stigma and Food Noise During Post‐Metabolic Bariatric Surgery Weight Stability

Obesity, EarlyView.
ABSTRACT Objective Food noise has been studied with GLP‐1‐based therapies, but not with metabolic bariatric surgery (MBS), despite shared mechanisms. Data on food noise beyond initial weight loss are limited, and weight self‐stigma (WSS), which links to poorer weight outcomes and risky behaviors after MBS, may relate to higher food noise, especially ...
Dale S. Bond, Yin Wu, Pavlos K. Papasavas, Michael E. Levin, Rebecca M. Puhl, Dahlia Saad‐Pendergrass, Devika Umashanker, Darren Tishler, Jason Lillis   +8 more
wiley   +1 more source

Successful Pregnancy in a Patient with Crohn's Disease and Short Bowel Syndrome: Off Total Parenteral Nutrition and On Teduglutide, a Glucagon-Like Peptide-2 Analog - A Case Report. [PDF]

Case Rep Gastroenterol
Dahar MM, Both M, Lord LM, Densmore C, Saubermann LJ.   +4 more
europepmc   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists for Obstructive Sleep Apnea With and Without Continuous Positive Airway Pressure

Otolaryngology–Head and Neck Surgery, EarlyView.
Abstract Objective To evaluate glucagon‐like peptide 1 receptor agonists for obstructive sleep apnea compared with controls. Data Sources CINAHL, Cochrane Library, PubMed, and Scopus. Review Methods A PRISMA‐compliant search was conducted from database inception through October 2025.
Cali Loblundo, Sammy Y. Gao, Shaun A. Nguyen, Mohamed Abdelwahab   +3 more
wiley   +1 more source

From cytokine storm to renal scarring in diabetic kidney disease: Biomarkers, risk stratification, and precision therapeutics

Precision Medical Sciences, EarlyView.
Hyperglycemia‐driven cytokine activation initiates a sustained inflammatory cascade in diabetic kidney disease, promoting cellular injury and fibrogenic signaling. Integrating cytokine‐based biomarkers with risk stratification enables precision therapeutics that target inflammation and fibrosis, ultimately aiming to halt progression from early renal ...
Emmanuel Ifeanyi Obeagu
wiley   +1 more source

Optimizing peripubertal growth in a child with short bowel syndrome on full oral feeding with glucagon-like peptide 2 analog. [PDF]

JPGN Rep
Romanchuk A, Bravi M, Tebaldi P, D'Antiga L, Norsa L.   +4 more
europepmc   +1 more source